PP405 is ineffective for miniaturized, fibrosed hairfollicles in androgenetic alopecia. AMP303 may activate hairfollicle stem cells, but minoxidil and finasteride are still the main treatments.
HairClone is developing cell replacement treatments to rejuvenate and generate hairfollicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hairfollicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
The user is 10 days post-hair transplant, pleased with the results so far, and hopes for increased density. The procedure was done at Vanity Hospital in Istanbul, with around 3400-3750 grafts used.